Skip to content Skip to footer
Subscribe Now
SPOTLIGHT

CXO Talks: Vikas Sharma Reveals QurAlis’ Bold Vision for the Future of Neuroscience 

In this episode of CXO Talks, PharmaShots speaks with Vikas Sharma, Chief Business Officer at QurAlis, a biotech company leading the development of precision medicines for neurodegenerative diseases Vikas discusses the company’s FlexASO platform, a next-generation RNA-targeting technology that tackles the root causes of neurological diseases Vikas also highlights QurAlis’ lead candidates, QRL-201 and QRL-101,…
2 days ago

Read more

NEWS

Novartis to Acquire Avidity Biosciences for ~$12B, Boosting its Neuroscience Pipeline

Shots:Novartis has agreed to acquire Avidity Biosciences, strengthening its neuroscience pipeline with Avidity’s Antibody Oligonucleotide Conjugates (AOCs) platform & 3 late-stage programsAs per the deal, Novartis will acquire Avidity for $72/share, valuing the company at ~$12B with an enterprise value of ~$11B; closing expected in H1’26Before the merger, Avidity will transfer its early-stage precision…
October 27, 2025

Read more

AbbVie & ADARx Pharmaceuticals
NEWS

AbbVie Partners with ADARx Pharmaceuticals to Develop siRNA Therapies Across Multiple Disease Areas

Shots:AbbVie has entered into collaboration & license option agreement with ADARx to develop siRNA therapeutics across multiple disease areas, incl. neuroscience, immunology & oncology, leveraging ADARx's RNA techAs per the deal, ADARx will receive $335M upfront & will be eligible to receive several billion in additional contingent payments incl. option fees, milestones, plus tiered royalties…
May 15, 2025

Read more

Netramark & Worldwide Clinical Trials
NEWS

NetraMark Join Forces with Worldwide Clinical Trials to Redefine Clinical Trial Design Using NetraAI Platform

Shots:NetraMark and Worldwide Clinical Trials have entered into a global agreement to utilize NetraMark’s NetraAI platform to advance clinical trial designAs per the deal, NetraAI will initially support P-II neuroscience & oncology trials, plus select P-III studies conducted by Worldwide, with broader access extended to Worldwide’s sponsors across all therapeutic areas & trial…
April 4, 2025

Read more

VIEWPOINTS_Angela Cacace_2024
VIEWPOINTS

Transformative Neurodegenerative Disorder Care: Angela Cacace in Conversation with PharmaShots

Shots:Angela Cacace Sr. VP, of Neuroscience and Platform Biology at Arvinas, shares insights from the preclinical trials evaluating ARV-102 for treatment of neurodegenerative diseases and dosing people with the first oral formulation (ARV-102) to treat neurodegenerative diseasesARV-102, a novel oral PROTAC® protein degrader, is designed to cross the blood-brain barrier and target leucine-rich repeat kinase…
April 29, 2024

Read more

Viewpoints_Karl Bradshaw
VIEWPOINTS

Karl Bradshaw, VP of Corporate Development at Metabolon, Shares Insights on the Partnership with The University of Oxford Parkinson’s Disease Centre

Shots:Karl spoke on Metabolon’s partnership with the University of Oxford Parkinson’s Disease Centre (OPDC) to identify new metabolomic biomarkers for the advancement of Parkinson’s research Karl also talked about the metabolomic changes which occur in Parkinson’s disease and how Metabolon will support OPDC's mission to improve research and understanding of the biology of early…
September 21, 2022

Read more